We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

198 hedge funds and large institutions have $3.98B invested in Neurocrine Biosciences in 2015 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 52 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

226% more call options, than puts

Call options by funds: $61.7M | Put options by funds: $18.9M

167% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 15

67% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 52

18% more capital invested

Capital invested by funds: $3.38B → $3.98B (+$603M)

14% more funds holding

Funds holding: 174 → 198 (+24)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
198
Holders Change
+24
Holders Change %
+13.79%
% of All Funds
5.33%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
40
Increased
87
Reduced
52
Closed
15
Calls
$61.7M
Puts
$18.9M
Net Calls
+$42.8M
Net Calls Change
+$32.6M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$60.2M
2
Citadel Advisors
Citadel Advisors
Florida
+$17.8M
3
JHIU
Janus Henderson Investors US
Colorado
+$16.9M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$14.8M
5
Norges Bank
Norges Bank
Norway
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$47.3M
2
VAM
Visium Asset Management
New York
-$42.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$35.1M
4
O
OrbiMed
New York
-$31.3M
5
PA
Perceptive Advisors
New York
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
76
Wells Fargo
California
$5.22M +$372K +8,771 +9%
New York State Common Retirement Fund
77
New York State Common Retirement Fund
New York
$5.14M +$4.29M +101,238 +1,567%
CS
78
Candriam SCA
Luxembourg
$5.01M -$2.12M -50,000 -32%
CCM
79
Cadian Capital Management
New York
$4.79M +$4.26M +100,397 New
Swiss National Bank
80
Swiss National Bank
Switzerland
$4.64M +$220K +5,200 +6%
Prudential Financial
81
Prudential Financial
New Jersey
$4.2M – – –
RhumbLine Advisers
82
RhumbLine Advisers
Massachusetts
$4.17M -$53.6K -1,265 -1%
AA
83
ALPS Advisors
Colorado
$4.05M +$1.84M +43,292 +104%
NFA
84
Nationwide Fund Advisors
Ohio
$3.87M +$155K +3,653 +5%
PAM
85
Paradigm Asset Management
New York
$3.85M – – –
MAA
86
Managed Account Advisors
New Jersey
$3.83M +$384K +9,055 +13%
ProShare Advisors
87
ProShare Advisors
Maryland
$3.77M -$252K -5,936 -7%
ACM
88
Atika Capital Management
New York
$3.46M +$897K +21,150 +41%
Capital Fund Management (CFM)
89
Capital Fund Management (CFM)
France
$3.41M +$3.03M +71,367 New
EI
90
EAM Investors
California
$3.4M +$3.02M +71,132 New
AIG
91
American International Group
New York
$3.24M +$47.1K +1,110 +2%
State Board of Administration of Florida Retirement System
92
State Board of Administration of Florida Retirement System
Florida
$3.22M +$148K +3,482 +5%
BAMS
93
Bellevue Asset Management (Switzerland)
Switzerland
$3.1M +$1.06M +25,000 +63%
AL
94
Airain Ltd
Guernsey
$2.95M +$2.62M +61,692 New
Balyasny Asset Management
95
Balyasny Asset Management
Illinois
$2.87M +$2.54M +60,000 New
MLICM
96
Metropolitan Life Insurance Company (MetLife)
New York
$2.8M +$2.49M +58,684 New
VFA
97
Virtus Fund Advisers
Connecticut
$2.8M -$34.6K -816 -1%
DBG
98
De Burlo Group
Massachusetts
$2.74M -$42.4K -1,000 -2%
MAM
99
Meeder Asset Management
Ohio
$2.66M +$2.36M +55,665 New
ARTA
100
A.R.T. Advisors
New York
$2.65M +$141K +3,329 +6%
2 3
4
5 6

NBIX Hedge Fund Activity: Q2 2015 in Review

198 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2015, worth a combined $3.98B — up 18% from $3.38B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new NBIX positions and 15 closed out — a net gain of 25 holders — while 87 added to existing stakes and 52 trimmed.

The largest buyer was Vanguard Group, adding an estimated $60.2M. The largest seller was Westfield Capital Management, cutting an estimated $47.3M.

  • 198 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2015, up from 174 in Q1 2015.
  • Funds reported $3.98B of Neurocrine Biosciences stock for Q2 2015, up 18% quarter-over-quarter.
  • 40 funds opened new Neurocrine Biosciences positions in Q2 2015 and 15 closed out, a net change of +25 holders.
  • The largest Neurocrine Biosciences buyer in Q2 2015 was Vanguard Group, an estimated $60.2M added.
  • The largest Neurocrine Biosciences seller in Q2 2015 was Westfield Capital Management, an estimated $47.3M sold.

Based on aggregated 13F filings for Q2 2015.